Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer

References

• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–83.
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633–40.
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377–84.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365: 1687–717.
   Google Scholar
• Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24–35.
   PubMed Web of Science ®Google Scholar
• Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699–709.
   PubMed Web of Science ®Google Scholar
• Shah A, Maroun J, Dranitsaris G. The cost of hospitalization secondary to severe chemotherapy induced diarrhea (CID) in patients with colorectal cancer. J Clin Oncol 2004; 22:6111.
   Google Scholar
• von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011;47:2273–81.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27: 1999–2006.
   PubMed Web of Science ®Google Scholar
• Irish Life Tables, Central Statistics Office (CSO). [cited 2013 Mar 14]. Available from: http://www.cso.ie/en/media/duplicatecsomedia/newmedia/releasespublications/documents/birthsdm/current/irishlife.pdf.
   Google Scholar
• Norum J, Olsen JA, Wist EA, Lønning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost- effectiveness analysis. Acta Oncol 2007;46:153–64.
   Google Scholar
• Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A model-based analysis of the HERA and FinHer trial. Ann Oncol 2007;18:1493–9.
   PubMed Web of Science ®Google Scholar
• Mansel R, Locker G, Fallowfield L, Benedict A, Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial. Br J Cancer 2007;97:152–61.
   PubMed Web of Science ®Google Scholar
• Department of Health, National Positive Ageing Strategy, Irish Hospice submission. [cited 2013 Mar 14]. Available from: http://www.dohc.ie/issues/national_positive_ageing/Irish%20Hospice%20Foundation%20Submission.pdf? direct = 1.
   Google Scholar
• Dail Eireann, Joint Committee on Health and Children, 8 November 2012. [cited 2013 Mar 14]. Available from: http://oireachtasdebates.oireachtas.ie/Debates%20Authoring/DebatesWebPack.nsf/committeetakes/HEJ2012110800001?opendocument.
   Google Scholar
• Goss P, Smith I, O’Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F, et al. Results of a randomized, double-blind, multicenter, placebo-controlled study of adjuvant lapatinib in women with early-stage ErbB2-overexpressing breast cancer. Presented at the San Antonio Breast Cancer Symposium. San Antonio, TX, December 6–10, 2011.
   Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733–43.
   PubMed Web of Science ®Google Scholar
• Adjuvant lapatinib and/or trastuzumab treatment optimisation (ALTTO). [cited 2013 Mar 14]. Available from: http://www.alttotrials.com/
   Google Scholar
• Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2 + operable breast cancer: NSABP protocol B-41. 2012;(Suppl):LBA506.
   Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124–30.
   PubMed Web of Science ®Google Scholar
• Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009; 115:489–98.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE): Breast cancer (advanced or metastatic) – lapatinib: Appraisal consultation. [cited 2013 Mar 14]. Available from: http://www.nice.org.uk/guidance/index.jsp?action = article&o = 45725.
   Google Scholar
• Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–9.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007;25:634–41.
   PubMed Web of Science ®Google Scholar